Skip to main content
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 2003 Oct 2;42(2):213–216. doi: 10.1046/j.1365-2125.1996.40211.x

A cohort study of the ocular safety of anti-ulcer drugs

LUIS A GARCÍA RODRÍGUEZ 1, SALVATORE MANNINO 2, MARI-ANN WALLANDER 3,4, BERTIL LINDBLOM 5
PMCID: PMC2042664  PMID: 8864320

Abstract

  1. Recently, some cases have been reported where intravenous use of omeprazole was followed by loss of vision. We followed up a cohort of close to 140 000 persons during periods of treatment and non-treatment with five anti-ulcer drugs.

  2. The relative risk of vascular disorders of the eye during use of omeprazole compared with non-use was 1.8 (95% CI 0.5–6.0). Use of other anti-ulcer drugs was associated with a similar risk of vascular disorders. The relative risk associated with current use of any anti-ulcer drug was 1.9 (95% CI 1.1–3.4). We did not find a single case of optic inflammatory disorder during treatment with any of the five anti-ulcer drugs.

  3. These results do not suggest a major increased risk for vascular or inflammatory disorders of the eye associated with use of omeprazole or other anti-ulcer drugs.

Keywords: omeprazole, anti-ulcer drugs, ocular safety

Full Text

The Full Text of this article is available as a PDF (157.7 KB).


Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES